1. Medtech Insight
  2. >>Digital Technologies

Collecting Sensitive Data With AI Chatbots

 
• By Hannah Daniel

Medtech Insight spoke to QliqSOFT executive Bobbi Weber about the advantages of collecting patient data though chatbots, and how the technology can make conversations at the doctor’s office a little more manageable. 

• Source: Shutterstock

Sharing personal information with a doctor can be uncomfortable, but an AI chatbot might make the conversations a little less awkward.

It’s not just about the awkward conversation, though—in November 2023, the Centers for Medicare and Medicaid Services (CMS) added three...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

FDA’s New AI Councils Focus On ‘Responsible’ Adoption And Regulation

 
• By Sarah Karlin-Smith

The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By Elizabeth Orr

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By Elizabeth Orr

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

More from Medtech Insight

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

Medtech Must Address AI Risks Now Or Jeopardize Its Future Potential, Expert Warns

 
• By Amanda Maxwell

Urgent action is needed to address gaps in how risks from medical devices and diagnostics utilizing AI are identified, mitigated and managed. So says James Pink, renowned medtech regulatory expert in an interview with Medtech Insight.

Exercise Caution While Using Hyperbaric Oxygen Therapy Devices, FDA Warns

 
• By Brian Bossetta

The US FDA has published a list of recommendations for the safe use of hyperbaric oxygen therapy devices. While the therapy can be effective in treating several conditions, the agency says providers need to understand its potential risks.